Evidence map›Paper›PMID 26950068›Full record

ArticlePloS one2016

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization.

Vasileios A Stamelos, Natalie Fisher, Harnoor Bamrah, Carolyn Voisey, Joshua C Price, William E Farrell, Charles W Redman, Alan Richardson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Mechanisms of cancer cell death induction by paclitaxel: an updated review.Apoptosis : an international journal on programmed cell death · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Modulating lysosomal pH: a molecular and nanoscale materials design perspective.Journal of life sciences (Westlake Village, Calif.) · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. A Combination ofAntioxidants (Basel, Switzerland) · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vasileios A StamelosInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Natalie FisherInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Harnoor BamrahInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Carolyn VoiseyInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Joshua C PriceInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
William E FarrellInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Charles W RedmanUniversity Hospital of North Midlands, Stoke-on-Trent, Staffordshire, United Kingdom.
Alan RichardsonInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Keele University · GBUniversity Hospitals of North Midlands NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obatoclax belongs to a class of compounds known as BH3 mimetics which function as antagonists of Bcl-2 family apoptosis regulators. It has undergone extensive preclinical and clinical evaluation as a cancer therapeutic. Despite this, it is clear that obatoclax has additional pharmacological effects that contribute to its cytotoxic activity. It has been claimed that obatoclax, either alone or in combination with other molecularly targeted therapeutics, induces an autophagic form of cell death. In addition, obatoclax has been shown to inhibit lysosomal function, but the mechanism of this has not been elucidated. We have evaluated the mechanism of action of obatoclax in eight ovarian cancer cell lines. Consistent with its function as a BH3 mimetic, obatoclax induced apoptosis in three cell lines. However, in the remaining cell lines another form of cell death was evident because caspase activation and PARP cleavage were not observed. Obatoclax also failed to show synergy with carboplatin and paclitaxel, chemotherapeutic agents which we have previously shown to be synergistic with authentic Bcl-2 family antagonists. Obatoclax induced a profound accumulation of LC-3 but knockdown of Atg-5 or beclin had only minor effects on the activity of obatoclax in cell growth assays suggesting that the inhibition of lysosomal function rather than stimulation of autophagy may play a more prominent role in these cells. To evaluate how obatoclax inhibits lysosomal function, confocal microscopy studies were conducted which demonstrated that obatoclax, which contains two basic pyrrole groups, accumulates in lysosomes. Studies using pH sensitive dyes demonstrated that obatoclax induced lysosomal alkalinization. Furthermore, obatoclax was synergistic in cell growth/survival assays with bafilomycin and chloroquine, two other drugs which cause lysosomal alkalinization. These studies explain, for the first time, how obatoclax inhibits lysosomal function and suggest that lysosomal alkalinization contributes to the cytotoxic activity of obatoclax.

Indexed as

Biological TransportBiomimetic MaterialsCathepsinsCell DeathCell Line, TumorHumansHydrogen-Ion ConcentrationIndolesLysosomesProto-Oncogene Proteins c-bcl-2PyrrolesCathepsinsIndolesobatoclaxProto-Oncogene Proteins c-bcl-2Pyrroles

Identifiers

PMID26950068
PMCPMC4780728
OpenAlexW2295732678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.